Ironwood Pharmaceuticals (IRWD) News Today $1.34 -0.02 (-1.47%) Closing price 04/4/2025 04:00 PM EasternExtended Trading$1.34 +0.00 (+0.37%) As of 04/4/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Short Interest Up 34.9% in MarchIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Get Free Report) was the target of a large increase in short interest during the month of March. As of March 15th, there was short interest totalling 16,250,000 shares, an increase of 34.9% from the February 28th total of 12,050,000 shares. Based on an average daily trading volume, of 3,340,000 shares, the days-to-cover ratio is currently 4.9 days. Currently, 10.5% of the company's stock are sold short.April 1, 2025 | marketbeat.comIronwood Pharmaceuticals: Stability and Growth Potential Amid Internal Control ImprovementsMarch 31, 2025 | tipranks.comIronwood Pharmaceuticals (NASDAQ:IRWD) Stock Rating Upgraded by StockNews.comMarch 30, 2025 | americanbankingnews.comIronwood Pharmaceuticals (NASDAQ:IRWD) Rating Increased to Buy at StockNews.comStockNews.com upgraded shares of Ironwood Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Saturday.March 30, 2025 | marketbeat.comEquities Analysts Set Expectations for IRWD Q3 EarningsMarch 30, 2025 | americanbankingnews.comZacks Research Analysts Decrease Earnings Estimates for IRWDIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) - Zacks Research reduced their Q3 2026 earnings per share estimates for Ironwood Pharmaceuticals in a research note issued on Wednesday, March 26th. Zacks Research analyst R. Department now expects that the biotechnology company will postMarch 29, 2025 | marketbeat.comIronwood receives Nasdaq non-compliance notificationMarch 28, 2025 | markets.businessinsider.comIronwood Pharmaceuticals Announces Receipt of Nasdaq Non-Compliance Notification Regarding Late 2024 Form 10-K FilingMarch 27, 2025 | businesswire.comIndustry Veteran Launches Ironwood III With Substantial Equity Commitment From Kayne Anderson Energy Infrastructure FundMarch 25, 2025 | businesswire.comEquities Analysts Offer Predictions for IRWD Q2 EarningsIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) - Analysts at Zacks Research dropped their Q2 2025 EPS estimates for Ironwood Pharmaceuticals in a report issued on Thursday, March 20th. Zacks Research analyst R. Department now forecasts that the biotechnology company will post earningsMarch 24, 2025 | marketbeat.comIronwood Pharmaceuticals (NASDAQ:IRWD) Rating Lowered to "Hold" at StockNews.comStockNews.com lowered Ironwood Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Friday.March 21, 2025 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Buys 215,166 Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)Connor Clark & Lunn Investment Management Ltd. boosted its position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) by 170.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 341,455 shMarch 20, 2025 | marketbeat.comBillionaire Healthcare Investor Alex Denner's Hedge Fund Has 75% of Its Assets in These 3 StocksMarch 17, 2025 | 247wallst.comIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Receives Consensus Rating of "Moderate Buy" from AnalystsShares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Get Free Report) have been assigned an average rating of "Moderate Buy" from the six ratings firms that are currently covering the company, Marketbeat reports. Three research analysts have rated the stock with a hold recommendation and three hMarch 17, 2025 | marketbeat.comIronwood Pharmaceuticals (NASDAQ:IRWD) Upgraded by StockNews.com to "Buy" RatingStockNews.com raised shares of Ironwood Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Thursday.March 14, 2025 | marketbeat.comJupiter Asset Management Ltd. Sells 225,160 Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)Jupiter Asset Management Ltd. trimmed its position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) by 15.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,223,275 shares of the biotechnology companMarch 14, 2025 | marketbeat.comIronwood Pharma Delays 10-K Filing Due to Internal IssuesMarch 3, 2025 | tipranks.comIs Ironwood Pharmaceuticals, Inc. (IRWD) the Best Small Cap Pharma Stocks to Buy Now?March 2, 2025 | msn.comIs Ironwood Pharmaceuticals, Inc. (IRWD) the Best Small Cap Pharma Stock to Buy Now?March 2, 2025 | insidermonkey.comIronwood Pharmaceuticals (NASDAQ:IRWD) Stock Rating Lowered by StockNews.comStockNews.com lowered Ironwood Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Friday.March 1, 2025 | marketbeat.comLos Angeles Capital Management LLC Boosts Stock Holdings in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)Los Angeles Capital Management LLC lifted its position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) by 2,625.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 331,700 shMarch 1, 2025 | marketbeat.comIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Q4 2024 Earnings Call TranscriptMarch 1, 2025 | msn.comIronwood Pharmaceuticals (NASDAQ:IRWD) Issues Earnings Results, Misses Estimates By $0.08 EPSIronwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) released its quarterly earnings results on Thursday. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.08). Ironwood Pharmaceuticals had a negative return on equity of 0.96% and a negative net margin of 0.65%.February 28, 2025 | marketbeat.comIronwood Pharmaceuticals (NASDAQ:IRWD) Releases Quarterly Earnings ResultsIronwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) released its quarterly earnings data on Thursday. The biotechnology company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.08). Ironwood Pharmaceuticals had a negative return on equity of 0.96% and a negative net margin of 0.65%.February 28, 2025 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Ironwood Pharma (IRWD) and Intellia Therapeutics (NTLA)February 27, 2025 | markets.businessinsider.comIronwood Pharmaceuticals, Inc. (IRWD) Q4 2024 Earnings Call TranscriptFebruary 27, 2025 | seekingalpha.comIronwood Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Results; Achieves 2024 Financial GuidanceFebruary 27, 2025 | businesswire.comIronwood Pharmaceuticals Inc (IRWD) Q4 2024 Earnings Report Preview: What To Look ForFebruary 26, 2025 | gurufocus.comIronwood Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Investor Update CallFebruary 20, 2025 | investing.comIronwood Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Investor Update CallFebruary 20, 2025 | finance.yahoo.comIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Given Average Rating of "Moderate Buy" by BrokeragesIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the six analysts that are covering the firm, Marketbeat.com reports. Three investment analysts have rated the stock with a hold recommendation and three have issued a buy recoFebruary 20, 2025 | marketbeat.comShort Interest in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Rises By 13.8%Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Get Free Report) was the recipient of a significant growth in short interest in January. As of January 31st, there was short interest totalling 10,750,000 shares, a growth of 13.8% from the January 15th total of 9,450,000 shares. Based on an average daily trading volume, of 2,880,000 shares, the short-interest ratio is presently 3.7 days. Approximately 6.9% of the shares of the company are short sold.February 17, 2025 | marketbeat.comWhat is Zacks Research's Estimate for IRWD FY2025 Earnings?Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) - Equities researchers at Zacks Research lifted their FY2025 EPS estimates for Ironwood Pharmaceuticals in a research report issued on Wednesday, February 12th. Zacks Research analyst R. Department now forecasts that the biotechnology comFebruary 17, 2025 | marketbeat.comWhat is Zacks Research's Forecast for IRWD Q1 Earnings?Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) - Equities researchers at Zacks Research decreased their Q1 2025 earnings per share estimates for Ironwood Pharmaceuticals in a report released on Wednesday, February 12th. Zacks Research analyst R. Department now anticipates that the bioFebruary 15, 2025 | marketbeat.comARMISTICE CAPITAL, LLC Increases Stake in Ironwood Pharmaceuticals IncFebruary 15, 2025 | gurufocus.comIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Insider Ronald Silver Sells 12,048 SharesFebruary 13, 2025 | insidertrades.comIronwood Pharmaceuticals chief legal officer sells shares worth $68,530February 13, 2025 | msn.comIronwood Pharmaceuticals' principal accounting officer sells $21,204 in stockFebruary 13, 2025 | msn.comIronwood Pharmaceuticals (IRWD) to Release Earnings on ThursdayIronwood Pharmaceuticals (NASDAQ:IRWD) will be releasing earnings before the market opens on Thursday, February 20, Financial Modeling Prep reports.February 13, 2025 | marketbeat.comRonald Silver Sells 12,048 Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) StockIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Get Free Report) insider Ronald Silver sold 12,048 shares of the stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $1.76, for a total value of $21,204.48. Following the completion of the transaction, the insider now directly owns 279,655 shares in the company, valued at approximately $492,192.80. This represents a 4.13 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.February 12, 2025 | marketbeat.comIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD) CMO Michael Shetzline Sells 41,269 SharesIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Get Free Report) CMO Michael Shetzline sold 41,269 shares of Ironwood Pharmaceuticals stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $1.76, for a total transaction of $72,633.44. Following the completion of the transaction, the chief marketing officer now owns 554,007 shares of the company's stock, valued at $975,052.32. The trade was a 6.93 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.February 12, 2025 | marketbeat.comInsider Selling: Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) CEO Sells 139,064 Shares of StockIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Get Free Report) CEO Thomas A. Mccourt sold 139,064 shares of Ironwood Pharmaceuticals stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $1.76, for a total transaction of $244,752.64. Following the sale, the chief executive officer now owns 1,160,634 shares in the company, valued at $2,042,715.84. This represents a 10.70 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.February 12, 2025 | marketbeat.comMillrose Properties Set to Join S&P SmallCap 600February 5, 2025 | prnewswire.comSTATE STREET CORP Reduces Stake in Ironwood Pharmaceuticals IncFebruary 5, 2025 | gurufocus.comLeerink Partnrs Brokers Lower Earnings Estimates for IRWDIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) - Leerink Partnrs reduced their Q1 2025 earnings per share (EPS) estimates for Ironwood Pharmaceuticals in a report released on Wednesday, January 29th. Leerink Partnrs analyst F. Khurshid now anticipates that the biotechnology company wiFebruary 3, 2025 | marketbeat.comIronwood Pharmaceuticals Initiates Apraglutide NDA Submission, Highlights Compelling New Data and Updates Corporate Structure to Position for the FutureJanuary 31, 2025 | businesswire.comIronwood Pharma: Strategic Growth Amidst Challenges, Driven by Apra’s PotentialJanuary 31, 2025 | markets.businessinsider.comVanguard Group Inc Reduces Stake in Ironwood Pharmaceuticals IncJanuary 31, 2025 | gurufocus.comLeerink Partnrs Issues Negative Forecast for IRWD EarningsIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) - Equities research analysts at Leerink Partnrs cut their Q4 2024 earnings per share estimates for Ironwood Pharmaceuticals in a research note issued on Wednesday, January 29th. Leerink Partnrs analyst F. Khurshid now anticipates that theJanuary 31, 2025 | marketbeat.comIronwood Pharmaceuticals (NASDAQ:IRWD) Sets New 52-Week Low After Analyst DowngradeIronwood Pharmaceuticals (NASDAQ:IRWD) Sets New 1-Year Low After Analyst DowngradeJanuary 31, 2025 | marketbeat.com Remove Ads Get Ironwood Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for IRWD and its competitors with MarketBeat's FREE daily newsletter. Email Address IRWD Media Mentions By Week IRWD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IRWD News Sentiment▼0.230.61▲Average Medical News Sentiment IRWD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IRWD Articles This Week▼84▲IRWD Articles Average Week Remove Ads Get Ironwood Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for IRWD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Myriad Genetics News Rigel Pharmaceuticals News Verastem News Vanda Pharmaceuticals News Emergent BioSolutions News XOMA News Codexis News Sangamo Therapeutics News Regulus Therapeutics News Lexicon Pharmaceuticals News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IRWD) was last updated on 4/5/2025 by MarketBeat.com Staff From Our Partners“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredBrace Yourself for Jeff Bezos’ “Amazon Helios”Jeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredIt’s Time to Buy Elon’s “ChatGPT Killer”Elon Musk’s new AI model is blowing everyone’s mind. It has been called “a game-changer in AI innovation”.....Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ironwood Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ironwood Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy IRWD Stock Free IRWD Stock Alerts